id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S6254 R16664 |
Arkilo (Phenytoin), 2015 | Abnormal development (At 2 years of age, assessed by developmental specialists) | during pregnancy (anytime or not specified) | retrospective cohort | exposed to other treatment, sick | Adjustment: No | 0.96 [0.04;23.49] C | 0/5 2/24 | 2 | 5 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S6677 R18478 |
Dean (Phenytoin) (Controls exposed to Lamotrigine, sick), 2007 | Neurodevelopmental disorder (mean age in years: m1=11.6 and m0=1.5) | during pregnancy (anytime or not specified) | retrospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
3.84 [0.18;83.45] C excluded (control group) |
8/24 0/4 | 8 | 24 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S6672 R18467 |
Dean (Phenytoin) (Controls unexposed, sick), 2007 | Neurodevelopmental disorder (mean age in years: m1=11.6 and m0=15.25) | during pregnancy (anytime or not specified) | retrospective cohort | unexposed, sick | Adjustment: No | 7.17 [1.69;30.42] C | 8/24 3/46 | 11 | 24 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S7176 R20138 |
Adab (Phenytoin), 2004 | Any additional educational needs | during pregnancy (anytime or not specified) | retrospective cohort | unexposed, sick | Adjustment: No | 0.98 [0.36;2.68] | 7/22 28/87 | 35 | 22 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S6794 R19175 |
Katz (Phenytoin), 2001 | Developmental delay (Based on the DSM-IV-TR criteria) | during pregnancy (anytime or not specified) | retrospective cohort | exposed to other treatment, sick | Adjustment: No | 7.00 [0.22;218.96] C | 3/6 0/3 | 3 | 6 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 4 studies | 2.37 [0.65;8.62] | 51 | 57 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Phenytoin; 2: Phenytoin) (Controls unexposed, sick; 3: Phenytoin; 4: Phenytoin;
Asymetry test p-value = NaN (by Egger's regression)
not enought points
excluded 6677